



S not PNAS

Gaiger A
Cheever M

95 10152-157 1998

1444
#9

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 29 2001

TECH CENTER 1600/2900

Applicants: Hans Josef Strauss and Liquan Gao

US 5726 288

WO 95 29995 A1

Serial No.: 09/625,963

Art Unit: 1644

Filed: July 26, 2000

Examiner: Not Yet Assigned

For: *Immunotherapeutic Methods Using Epitopes of WT-1 and GATA-1*

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit an Information Disclosure Statement, including three (3) pages of Form PTO-1449 and a copy of each document cited therein.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1868.

U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
5,731,160	03-24-1998	Molief	435/7.24

Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
WO 91/17509 A1	05-30-1991	Massachusetts Institute of Technology	PCT

RECEIVED

AUG 29 2001

PCT TECH CENTER 1600/2900

WO 95/29995 A1	11-19-1995	The Wistar Institute of Anatomy and Biology	PCT
WO 97/26328 A1	07-24-1997	RPMS Technology Limited	PCT
WO 00/06602 A1	02-10-2000	H. Sugiyama	PCT
WO 00/18795 A2	04-06-2000	Corixa Corporation	PCT
10 218093	07-31-1999	H. Sugiyama	JP



Publications

AL-ODEIDI, et al., "Peptide and peptidomimetic libraries," *Molecular Biotechnology* 9:205-223 (1998).

BEELEY, "Peptidomimetics and small-molecule drug design: towards improved bioavailability and *in vivo* stability," *TIBTECH* 12:213-216 (1994).

BOTTGER, et al., "Molecular characterization of the hdm2-p53 interaction," *J Mol Biol* 269:744-756 (1997).

CROSSLEY & ORKIN, "Phosphorylation of the Erythroid Transcription Factor GATA-1," *J Bio Chem* 269:16589-96 (1994).

GAIGER, et al., "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," *Blood* 96(4):1480-89 (2000).

GAO, et al., "Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specif for WT1," *Blood* 95:2198-2203 (2000).

KIEBER-EMMONS, et al., "Therapeutic peptides and peptidomimetics," *Curr Opinion Biotechnol* 8:436-441 (1997).

MEZIERE, et al., "In vivo helper cell response to retro-inverso peptidomimetics," *Journal of Immunology* 159:3230-37 (1997).

MURALI & GREENE, "Structure-based design of immunologically active therapeutic peptides," *Immunolgc Research* 17(1&2):163-169 (1998).

NAKANISHI, et al., "Peptidomimetics of the immunoglobulin supergene family – a review," *Gene* 137:51-56 (1993).

OHMINAMI, et al., "HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide," *Blood* 95:286-93 (2000).

OKA, et al., "Cancer immunotherapy targeting Wilms' Tumor Gene WT1 product," *J Immunol* 164:1873-80 (2000).


OKA, et al., "Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms tumor (WT1) product," *Immunogenetics* 51:99-107 (2000).

SADOVNIKOVA & STAUSS, "Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy," *Proc Natl Acad Sci USA* 93:13114-13118 (1996).

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Dated: August 23, 2001


HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400
404-817-8500
FAX 404-817-0470
www.hklaw.com

U.S.S.N.: 09/625,963
Filed: July 26, 2000
INFORMATION DISCLOSURE STATEMENT

Certificate of Mailing under 37 C.F.R. § 1.8(a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: August 23, 2001



Kimberly L. Adams